Colorectal News and Research

RSS

Overall cancer mortality rates continue to decrease, new report shows

The continued drop in overall cancer mortality rates over the last 20 years has averted more than three-quarters of a million (767,000) cancer deaths according to a new report from the American Cancer Society. The American Cancer Society's annual Cancer Statistics article reports that the overall death rate from cancer in the United States in 2007 was 178.4 per 100,000, a relative decrease of 1.3 percent from 2006, when the rate was 180.7 per 100,000, continuing a trend that began in 1991 for men and 1992 for women.

8 Jul 2010

Heart attack death rates drop in hospitals; CDC reports increase in colon cancer screening rate

USA Today: Hospital heart attack death rates fell, according to new Medicare data. "Death rates at 4,569 hospitals that treat Medicare patients who suffer heart attacks fell by almost half a percentage point, from a national average of 16.6% last year to 16.2%. Death rates for most hospitals ranged from about 14.5% to 17.9%. ...

8 Jul 2010

Data on activity of Nektar's NKTR-102 in gastrointestinal cancer presented at ESMO 12th World Congress

Nektar Therapeutics announced today that data presented at the European Society for Medical Oncology (ESMO) 12th World Congress on Gastrointestinal Cancer demonstrates that NKTR-102, the company's lead oncology compound, exhibits superior activity compared to irinotecan as part of either a monotherapy or combination regimen in tumor models of gastrointestinal cancers.

7 Jul 2010

Combination of Biothera's Imprime PGG and Erbitux doubles response rate in colorectal cancer patients

The combination of Biothera's experimental drug Imprime PGG® and Erbitux® (cetuximab) doubled the historical overall response rate and the time to progression of second- and third-line metastatic colorectal cancer patients treated with Erbitux monotherapy. The data was released last weekend at the 13th World Congress on Gastrointestinal Cancer at the European Society for Medical Oncology (ESMO).

7 Jul 2010

Neogenix Oncology files patent application with USPTO for 16C3 antigen

Neogenix Oncology announced today that the company has filed a patent application with the U.S. Patent and Trade Office (USPTO) for the 16C3 antigen. The Company believes that this antigen is tumor specific for pancreatic and colorectal tumors; and, based on preliminary clinical data, may also have diagnostic utility as a biomarker for these cancers.

3 Jul 2010

Blacks often diagnosed with advanced cancer, more likely to have other underlying health problems

Black people with cancer are up to twice as likely as other races to die from their disease. While disparities exist for nearly every common cancer type, the largest differences occur among cancers that benefit most from treatment -- suggesting that black patients are not getting needed lifesaving treatments, according to a review from researchers at the University of Michigan Comprehensive Cancer Center.

2 Jul 2010

Survey: 66% of patients with metastatic colorectal cancer are now tested for KRAS

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has revealed new results from a global survey demonstrating that 66% of patients with metastatic colorectal cancer (mCRC) are now tested for KRAS to determine if they could benefit from a personalized therapy, such as Erbitux® (cetuximab). This represents a 50% increase in levels of KRAS testing in just one year.

1 Jul 2010

USPTO issues Notice of Allowance for patent application related to Neogenix Oncology's 16C3 antibody

Neogenix Oncology announced today that the U.S. Patent and Trade Mark Office has issued a Notice of Allowance for a patent application related to its 16C3 antibody. Discovered and developed by Neogenix Oncology, this antibody appears to have anti-tumor activity for both pancreatic and colorectal tumors, and may have both therapeutic and diagnostic utility. The antibody may have activity in other tumors as well, which the company will explore at such time as it prepares a pre-IND package for FDA review and designs a clinical trial for the 16C3 antibody.

1 Jul 2010

EMA grants Scientific Advice to Aeterna Zentaris for Phase 3 trial of anticancer compound perifosine

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has received positive Scientific Advice from the European Medicines Agency (EMA) regarding the Phase 3 trial initiated last April for the development of its lead anticancer proprietary compound, perifosine, in refractory advanced colorectal cancer.

30 Jun 2010

Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress

Keryx Biopharmaceuticals, Inc. today announced that abstract O-0017, entitled "Subset Analysis of 5-FU Refractory Patients from a Randomized Ph II Study of Perifosine + Capecitabine (P-CAP) vs. Placebo + Capecitabine (CAP) in Patients with 2nd or 3rd Line Metastatic CRC" has been selected for oral presentation at the upcoming 12th World Congress on Gastrointestinal Cancer, to be held in Barcelona, Spain from June 30 - July 2, 2010.

30 Jun 2010

Aeterna Zentaris receives positive Scientific Advice from EMA for perifosine Phase 3 trial in colorectal cancer

29 Jun 2010

Signature Dx obtains worldwide license to Affymetrix microarray technology for development of CRC tests

Affymetrix, Inc. and Signature Diagnostics AG today announced that they have signed a Powered by Affymetrix™ (PbA) agreement. Under the agreement, Signature Dx obtains a worldwide license to use Affymetrix® microarray technology to develop and commercialize diagnostic and prognostic colorectal cancer (CRC) tests.

29 Jun 2010

Scancell, immatics collaborate to develop ImmunoBody vaccines for colorectal cancer

Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, today announces a research collaboration with immatics biotechnologies GmbH to explore the development of novel ImmunoBody® vaccines for colorectal cancer.

29 Jun 2010

Lead researchers develop a novel technique to deliver cancer drugs

A new way to deliver cancer drugs using gas bubbles and sound waves is to be developed at the University of Leeds. The project will enable highly toxic drugs to be delivered in small doses directly to tumours, where their toxicity can safely be put to good use.

29 Jun 2010

Research on safety of endoscopic piecemeal mucosal resection in treatment of large sessile colorectal polyps

Endoscopic resection of large sessile colorectal polyps is increasingly used as an alternative to surgery, but remains challenging because of its technical difficulty, the high risk of complications such as bleeding or perforation, and the possibility of coexisting malignancy.

25 Jun 2010

Latino population less likely to receive basic preventive tests, says study

"Prevention" is the new buzzword for health professionals and the new emphasis for containing future health care costs. Yet Latinos, who currently represent about 15 percent of the U.S. population, have the lowest level of preventive care of all racial and ethnic groups in the nation.

25 Jun 2010

Hydrophobic proteins may serve as biomarkers for treating colorectal cancer

Colorectal cancer, cancer of the colon and rectum, is a common cause of mortality worldwide. Statistical data showed that the number of deaths caused by colorectal cancer is increasing in both men and women.

25 Jun 2010

Patent application for tumor specific NPC-1C Antigen filed by Neogenix Oncology

Neogenix Oncology announced today that it has filed a patent application with the US Patent and Trade Office for the NPC-1C antigen. This antigen appears to be tumor specific for pancreatic and colorectal tumors.

24 Jun 2010

Nektar commences dosing in Phase 1 study of NKTR-102 in combination with 5-FU/leucovorin

Nektar Therapeutics announced today that the first patients have been dosed in a new Phase 1 dose-escalation clinical study to evaluate NKTR-102, the company's lead oncology compound, in combination with 5-fluorouracil (5-FU)/leucovorin in refractory solid tumor cancers. The study is being conducted at University Hospitals Case Medical Center of the Case Comprehensive Cancer Center in Cleveland, Ohio.

24 Jun 2010

Cancer Research UK launches new cutting-edge research centre at Imperial

A new cutting-edge cancer centre dedicated to robotic surgery, cancer imaging and drug discovery is launched today, putting London at the forefront of cancer research.

24 Jun 2010

Colorectal News and Research

Overall cancer mortality rates continue to decrease, new report shows

Heart attack death rates drop in hospitals; CDC reports increase in colon cancer screening rate

Data on activity of Nektar's NKTR-102 in gastrointestinal cancer presented at ESMO 12th World Congress

Combination of Biothera's Imprime PGG and Erbitux doubles response rate in colorectal cancer patients

Neogenix Oncology files patent application with USPTO for 16C3 antigen

Blacks often diagnosed with advanced cancer, more likely to have other underlying health problems

Survey: 66% of patients with metastatic colorectal cancer are now tested for KRAS

USPTO issues Notice of Allowance for patent application related to Neogenix Oncology's 16C3 antibody

EMA grants Scientific Advice to Aeterna Zentaris for Phase 3 trial of anticancer compound perifosine

Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress

Aeterna Zentaris receives positive Scientific Advice from EMA for perifosine Phase 3 trial in colorectal cancer

Signature Dx obtains worldwide license to Affymetrix microarray technology for development of CRC tests

Scancell, immatics collaborate to develop ImmunoBody vaccines for colorectal cancer

Lead researchers develop a novel technique to deliver cancer drugs

Research on safety of endoscopic piecemeal mucosal resection in treatment of large sessile colorectal polyps

Latino population less likely to receive basic preventive tests, says study

Hydrophobic proteins may serve as biomarkers for treating colorectal cancer

Patent application for tumor specific NPC-1C Antigen filed by Neogenix Oncology

Nektar commences dosing in Phase 1 study of NKTR-102 in combination with 5-FU/leucovorin

Cancer Research UK launches new cutting-edge research centre at Imperial

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News